Presenter name:Noel Juban, M.D, MsC

Affiliation: Department of Clinical Epidemiology

U.P. College of Medicine

November 2011MeTA

Process and Lessons from the Pharmaceutical Sector Scan –

the PhilippinesWHO Harvard Collaborating Center in Pharmaceutical Policy

on behalf ofThe Medicines Transparency Alliance

 

Introduction

The Pharmaceutical Sector Scan intends to:

Collect, organize, and synthesize data on the Pharmaceutical Sector

Highlight availability and gaps in key information Help MeTA stakeholder groups improve transparency

in the pharmaceutical sector and to set priorities for future activities

November 2011

Domains

1) Country Profile2) Medicines Policy and Regulatory Framework3) Medicines Market4) Medicines Financing5) Medicines Trade6) Medicines Supply System7) Medicines Access8) Medicines Use

November 2011

Methodology

November 2011

Background Scan (International Sources)

Background Scan (National Sources)

Key Informants for National Data

Data CollectionCollate and synthesize data

Verify Collated Data with Key Informants

Formulation of Recommendation

November 2011

Domain Name Total Fields

Completed Fields

Estimated Fields

Data available

upon request

No data

Country Profile: Demographic and Socioeconomic Indicators. Morbidity and mortality

54 53 1 0 0

Medicines Policy and Regulatory Framework

11 11 0 0 0

Medicines Market 8 6 2 0 0

Medicines Financing 23 20 3 0 0

Medicines Trade 75 61 1 7 6

Medicines Supply System 54 33 0 2 19

Medicines Access 11 6 0 0 5

Medicines Use 34 31 0 0 3

Some indicators collated

GNI per capita: PhP 80,268.86 – (low to middle income country)

Health expenditure as % GDP: 3.8% Population covered PhilHealth (% of total

population): 76% according to PhilHealth Practicing Physicians: 3/10,000 population FDA (by virtue of RA 3720 and RA 9711) have 249

regulatory staff nationwide Estimated time to decision (from FDA):

– Patented products take around 180 to 270 days (6 to 9 months)

– Generic products take around 90 to 180 days (3 to 6 months)

November 2011

Some indicators collated 40% estimated market share of generic medicines Drug procurement monitoring

– Central procurement is monitored– Decentralized procurement has no system

Signatory of the World International Property Organizations’ conventions on intellectual property; local IP Laws: RA 8293 and RA 9502

60% of key medicines are available at public health care facilities, 96.7% in private facilities

November 2011

Key indicators collated

On prescribing– RA 6675 (Generics Act of 1988), and DOH AO 1989-062 and

1990-090 – RA 6675 on mandatory inclusion of generic names– PMA Code of Conduct has no specific reference to conduct

regarding prescribing medicines 84% of medicines are prescribed by the INN name despite the

Generics Act of 1988 mandating all prescriptions to use the generic or INN name.

92.9% of medicines are adequately labeled Only 52.9% of patients know how to take the medicine

November 2011

Some challenges encountered

• Conflicting data from various sources • Some information not available online

•Sites are under construction•Content unavailable

• Long gaps between published data and online data• Much of the time for data collection was spent on key-informant interviews• Of all data fields to be filled

• 2.59% were based on estimates from experts in the field• 3.33% were not disclosed due to privacy reasons and had to be requested • 11.48% had no actual data

November 2011

Conclusions

November 2011

• The scan is a comprehensive, user friendly tool

• An extensive source of data on medicine access, use and regulation can be obtained from the scan

• Performance of the pharmaceutical sector based on internationally accepted indicators of good governance and transparency were described

• Some obstacles to a total transparency identified

Good morning!